@ModernRetina profile picture
Modern Retina @ModernRetina

The leading source for #Retina. We cover AMD, DME, diabetic retinopathy, uveitis, and more. Follow our parent publication @OphthTimes.

Joined April 2019
  • Tweets 12,378
  • Following 538
  • Followers 2,785
8,458 Photos and videos
How are next-generation anti-VEGF agents changing care in AMD, DME, and RVO? Sharon Fekrat, MD, FACS, FASRS, and an expert panel discuss the real-world performance, durability, and safety of aflibercept 8 mg and faricimab. Watch now: hubs.li/Q04jplPR0 #Retina #AntiVEGF
1
2
89
As aesthetic injectables continue to grow in popularity, retina specialists are increasingly likely to encounter patients considering these procedures. Watch the latest episode of The Retina TL;DR to learn more: hubs.li/Q04gSSyR0
0:24
2
2
103
Jennifer Murdock, MD, joins The Retina TL;DR with Christina Y. Weng, MD, MBA, FASRS, to discuss filler-related ocular complications, high-risk injection sites, emergency management strategies, and more. Watch now: hubs.li/Q04gSpP00
1:05
2
166
Watch Christina Y. Weng, MD, MBA, FASRS, and her guest Jennifer Murdock, MD, discuss anatomy, vascular occlusion risk, and periocular filler safety in the latest episode of The Retina TL;DR: hubs.li/Q04gSC8Q0
0:24
1
1
199
Prevent Blindness has designated April as Women’s Eye Health and Safety Month. We are proud to support this initiative and highlight the voices shaping the future of care. Explore insights from female key opinion leaders whose recent work is featured on our platforms.
0:14
3
85
We are hosting two events for retina specialists in Fort Lauderdale, FL, on May 15. Participants will receive $500 in compensation. Learn more and join us! Geographic Atrophy Roundtable: hubs.li/Q04dq6Sv0 Anti-VEGF Roundtable: hubs.li/Q04dqkxz0
1
84
Honoring the women who are shaping the future of vision. From groundbreaking research to everyday patient care, their leadership and dedication continue to move the field forward. This Women’s History Month, we recognize their impact across every corner of eye care.
0:08
3
124
Check out the latest issue of Modern Retina! Read about how AI is reshaping ophthalmology, mitigating severe vision loss, multimodal imaging for AMD and GA, as well as mentorship, momentum, and a retina podcast. Read now: hubs.li/Q0450NXy0 #Retina #VisionLoss #AMD #GA
0:30
1
8
268
Disease mechanisms and treatment goals differ across AMD, DME, and RVO. Our expert panel reviews clinical nuances and how they guide the choice of next-generation anti-VEGF therapy. Watch the discussion: hubs.li/Q03_z0wF0 #Retina #Ophthalmology
1
1
201
Our latest issue is live! Read about the science powering next-generation retinal treatments, custom programs for managing Macular Telangiectasia, and treatment options for reducing fluid fluctuation in retinal disorders. Read now: hubs.li/Q03ZZ87N0 #Retina #MacTel
0:30
1
1
224
How are next-generation anti-VEGF agents changing care in AMD, DME, and RVO? Sharon Fekrat, MD, FACS, FASRS, and an expert panel discuss the real-world performance, durability, and safety of aflibercept 8 mg and faricimab. Watch now: hubs.li/Q03Y_T990 #Retina #AntiVEGF
180
Wishing you a season filled with clear moments and bright perspectives. 🎄👁️ Thank you to the retina specialists whose precision and dedication protect sight at its most critical level, today and all year long. #EyeCareProfessionals #RetinaCare #HappyHolidays
3
204
Grateful for the eye-care professionals who bring clarity, comfort, and better vision to patients every day. Wishing you a spec-tacular 👓 and restorative Thanksgiving! 🦃 #thanksgiving #eyecare
0:08
2
239
Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). hubs.li/Q03Vn_yh0

Coave Therapeutics reveals lead gene therapy program, CoTx-10 | Modern Retina

CoTx-10 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

modernretina.com
1
4
307
Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients. hubs.li/Q03Vp8Yp0

Q&A: Stephen Tsang discusses outcomes in retinitis pigmentosa and Stargardt trials | Modern Retina

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

modernretina.com
1
2
4
359
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME: hubs.li/Q03Vn_TX0

Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME |...

Behind the scenes of building impactful educational platforms in retina care

modernretina.com
1
2
206
Q&A: Kenneth Fan on MCO-010 trials for Stargardt disease: hubs.li/Q03VhpLR0

Q&A: Kenneth Fan on MCO-010 trials for Stargardt disease | Modern Retina

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

modernretina.com
1
294
Foundation Fighting Blindness releases 4-year RUSH2A data to public: hubs.li/Q03VshzK0

Foundation Fighting Blindness releases 4-year RUSH2A data to public | Modern Retina

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

modernretina.com
1
126
Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression: hubs.li/Q03Vhdhj0

Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression | Modern Retina

In the study, authors investigated the natural history of GA lesion incidence rates and analyzed potential risk factors for faster incidence of GA lesions.

modernretina.com
1
1
150
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial: hubs.li/Q03TM2_00

Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial | Modern Retina

The trial will be evaluating AXPAXLI dosed every 6 months vs aflibercept (2 mg) dosed every 8 weeks in treatment-naive patients with wet AMD.

modernretina.com
1
127
Load more